14.65 USD
0 (0%)
14.9 USD
+0.25 (+1.71%)
Taking everything into account, CLPT scores 3 out of 10 in our fundamental rating. CLPT was compared to 185 industry peers in the Health Care Equipment & Supplies industry. While CLPT seems to be doing ok healthwise, there are quite some concerns on its profitability. CLPT is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- CLPT had negative earnings in the past year.
- In the past year CLPT has reported a negative cash flow from operations.
- CLPT had negative earnings in each of the past 5 years.
- In the past 5 years CLPT always reported negative operating cash flow.
1.2 Ratios
- CLPT has a Return On Assets of -38.34%. This is in the lower half of the industry: CLPT underperforms 62.70% of its industry peers.
- With a Return On Equity value of -145.77%, CLPT is not doing good in the industry: 67.03% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -38.34% | ||
| ROE | -145.77% | ||
| ROIC | N/A |
ROA(3y)-43.22%
ROA(5y)-34.92%
ROE(3y)-74.46%
ROE(5y)-107.56%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- CLPT's Gross Margin of 61.31% is fine compared to the rest of the industry. CLPT outperforms 62.70% of its industry peers.
- CLPT's Gross Margin has declined in the last couple of years.
- CLPT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 61.31% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.19%
GM growth 5Y-1.52%
2. Health
2.1 Basic Checks
- CLPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for CLPT has been increased compared to 1 year ago.
- The number of shares outstanding for CLPT has been increased compared to 5 years ago.
- CLPT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- Based on the Altman-Z score of 1.21, we must say that CLPT is in the distress zone and has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of 1.21, CLPT is in line with its industry, outperforming 51.89% of the companies in the same industry.
- A Debt/Equity ratio of 1.84 is on the high side and indicates that CLPT has dependencies on debt financing.
- With a Debt to Equity ratio value of 1.84, CLPT is not doing good in the industry: 80.54% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.84 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.21 |
ROIC/WACCN/A
WACC10.02%
2.3 Liquidity
- CLPT has a Current Ratio of 6.37. This indicates that CLPT is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 6.37, CLPT belongs to the top of the industry, outperforming 83.24% of the companies in the same industry.
- A Quick Ratio of 5.56 indicates that CLPT has no problem at all paying its short term obligations.
- Looking at the Quick ratio, with a value of 5.56, CLPT belongs to the top of the industry, outperforming 84.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.37 | ||
| Quick Ratio | 5.56 |
3. Growth
3.1 Past
- The earnings per share for CLPT have decreased strongly by -21.74% in the last year.
- The Revenue has grown by 12.83% in the past year. This is quite good.
- The Revenue has been growing by 22.85% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-21.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
Revenue 1Y (TTM)12.83%
Revenue growth 3Y24.41%
Revenue growth 5Y22.85%
Sales Q2Q%9.1%
3.2 Future
- Based on estimates for the next years, CLPT will show a small growth in Earnings Per Share. The EPS will grow by 3.12% on average per year.
- The Revenue is expected to grow by 32.35% on average over the next years. This is a very strong growth
EPS Next Y-20.94%
EPS Next 2Y-8.31%
EPS Next 3Y3.12%
EPS Next 5YN/A
Revenue Next Year14.96%
Revenue Next 2Y32.03%
Revenue Next 3Y32.35%
Revenue Next 5YN/A
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for CLPT. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLPT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.31%
EPS Next 3Y3.12%
5. Dividend
5.1 Amount
- CLPT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
14.65
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)01-12 2026-01-12/amc
Earnings (Next)05-11 2026-05-11
Inst Owners40%
Inst Owner Change-0.05%
Ins Owners4.98%
Ins Owner Change0.01%
Market Cap435.84M
Revenue(TTM)34.33M
Net Income(TTM)-23.14M
Analysts82.5
Price Target29.58 (101.91%)
Short Float %10.68%
Short Ratio3.6
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-2.94%
Min EPS beat(2)-2.94%
Max EPS beat(2)-2.94%
EPS beat(4)0
Avg EPS beat(4)-15.18%
Min EPS beat(4)-34.8%
Max EPS beat(4)-2.94%
EPS beat(8)3
Avg EPS beat(8)-2.06%
EPS beat(12)5
Avg EPS beat(12)-4.56%
EPS beat(16)8
Avg EPS beat(16)-0.96%
Revenue beat(2)0
Avg Revenue beat(2)-5.65%
Min Revenue beat(2)-9.51%
Max Revenue beat(2)-1.8%
Revenue beat(4)1
Avg Revenue beat(4)-4.32%
Min Revenue beat(4)-9.51%
Max Revenue beat(4)1.45%
Revenue beat(8)5
Avg Revenue beat(8)-0.07%
Revenue beat(12)6
Avg Revenue beat(12)-1.31%
Revenue beat(16)8
Avg Revenue beat(16)-0.41%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-8.11%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.9%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.79%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 12.69 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 27.46 | ||
| P/tB | 27.46 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.84
EYN/A
EPS(NY)-0.82
Fwd EYN/A
FCF(TTM)-0.46
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS1.15
BVpS0.53
TBVpS0.53
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -38.34% | ||
| ROE | -145.77% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 61.31% | ||
| FCFM | N/A |
ROA(3y)-43.22%
ROA(5y)-34.92%
ROE(3y)-74.46%
ROE(5y)-107.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.19%
GM growth 5Y-1.52%
F-Score4
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.84 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 91.43% | ||
| Cap/Sales | 2.14% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.37 | ||
| Quick Ratio | 5.56 | ||
| Altman-Z | 1.21 |
F-Score4
WACC10.02%
ROIC/WACCN/A
Cap/Depr(3y)225.04%
Cap/Depr(5y)185.37%
Cap/Sales(3y)3.62%
Cap/Sales(5y)3.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
EPS Next Y-20.94%
EPS Next 2Y-8.31%
EPS Next 3Y3.12%
EPS Next 5YN/A
Revenue 1Y (TTM)12.83%
Revenue growth 3Y24.41%
Revenue growth 5Y22.85%
Sales Q2Q%9.1%
Revenue Next Year14.96%
Revenue Next 2Y32.03%
Revenue Next 3Y32.35%
Revenue Next 5YN/A
EBIT growth 1Y-20.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year32.42%
EBIT Next 3Y25.55%
EBIT Next 5YN/A
FCF growth 1Y17.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y16.21%
OCF growth 3YN/A
OCF growth 5YN/A
CLEARPOINT NEURO INC / CLPT FAQ
What is the fundamental rating for CLPT stock?
ChartMill assigns a fundamental rating of 3 / 10 to CLPT.
What is the valuation status of CLEARPOINT NEURO INC (CLPT) stock?
ChartMill assigns a valuation rating of 0 / 10 to CLEARPOINT NEURO INC (CLPT). This can be considered as Overvalued.
What is the profitability of CLPT stock?
CLEARPOINT NEURO INC (CLPT) has a profitability rating of 1 / 10.
What is the financial health of CLEARPOINT NEURO INC (CLPT) stock?
The financial health rating of CLEARPOINT NEURO INC (CLPT) is 4 / 10.